Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Chubb
Teva
US Army
Argus Health
Accenture
QuintilesIMS
Merck
Healthtrust

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,365,514

« Back to Dashboard

Which drugs does patent 9,365,514 protect, and when does it expire?

Patent 9,365,514 protects ALECENSA and is included in one NDA.

This patent has twenty-one patent family members in seventeen countries.
Summary for Patent: 9,365,514
Title:Composition comprising tetracyclic compound
Abstract: A composition which comprises substance represented by Formula (I), ##STR00001## [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.
Inventor(s): Furumoto; Kentaro (Gotemba, JP), Shiraki; Koji (Gotemba, JP), Hirayama; Tomoaki (Tokyo, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:13/816,804
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound;

Drugs Protected by US Patent 9,365,514

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Hoffmann-la Roche ALECENSA alectinib hydrochloride CAPSULE;ORAL 208434-001 Dec 11, 2015 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,365,514

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2010-185385Aug 20, 2010
PCT Information
PCT FiledAugust 19, 2011PCT Application Number:PCT/JP2011/068735
PCT Publication Date:February 23, 2012PCT Publication Number: WO2012/023597

International Family Members for US Patent 9,365,514

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083246 ➤ Try a Free Trial
Australia 2011291708 ➤ Try a Free Trial
Brazil 112013003879 ➤ Try a Free Trial
Canada 2808210 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Julphar
Boehringer Ingelheim
Teva
Express Scripts
Moodys
US Department of Justice
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.